Skip to main content

Advertisement

Table 1 Patients baseline characteristics

From: Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma

No. of patients 173
Follow-up median (min-max) [months] 27.5 (0.4-200.8)
Gender: males-females 37.5%-62.5%
Age median (range) [years] 64 (30–84)
ISS stage: I-II-III 30.3%-31.9%-37.8%
Durie-Salmon stage: I-II-III 6.5%-14.6%-78.9%
Durie-Salmon substage: A-B 79.8%-20.2%
Ig isotype: IgG-IgA-IgM-FLC-NonSecr. 62.3%-23.6%-0.9%-12.3%-0.9%
Light chains: kappa-lambda 66%-34%
No. of previous treatment lines
    None (First line treatment) 79 (56.0%)
    One 18 (12.8%)
    Two 16 (11.3%)
    More (>2) 28 (19.9%)
Treatment regimen
    Bortezomib 50 (43.1%)
    Thalidomid 40 (34.5%)
    Lenalidomide 26 (22.4%)
Biochemical parameter
    Haemoglobin (g/l) 103.5 (73–157)
    Thrombocytes (count x109) 193 (33–416)
    Calcium (mmol/l) 2.3 (0.0-13.9)
    Albumin (g/l) 38.3 (3.76-50.4)
    Creatinine (umol/l) 101 (11–932)
    β2-microglobulin (mg/l) 4.07 (1.1-42.6)
    Lactate dehydrogenase (ukat/l) 3.39 (1.71-30.89)
    C-reactive protein (mg/l) 4.15(0–174.3)
    Monoclonal Ig (g/l) 31.05 (0–95.6)
    Plasma cell infiltration of bonemarrow (%) 32.8 (1.6-93.6)
Chromosomal abnormality
    13q14 deletion 75 (55.1%)
    17p13 deletion 19 (13.6%)
    Translocation t(4;14) 18 (14.3%)
    1q21 gain 64 (46.7%)
    Hyperdiploidy 55 (42.0%)